Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/29/2005US20050288327 Small molecule inhibitors of HER2 expression
12/29/2005US20050288326 Combination therapy
12/29/2005US20050288325 Therapy for andropause using estrogen agonists/antagonists and testosterone
12/29/2005US20050288323 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine
12/29/2005US20050288322 Cyclizing 2,6-diaminopyridine in sulfuric acid with malic acid to form 2-amino-7-hydroxy-1,8-naphthyridine; phthalimidating the naphthyridine and replacing the OH with Cl; reducing the product to form the hydroxyindolinone derivative and etherifying with 5-methyl-2-oxo-hexyltriphenylphosphonium halide
12/29/2005US20050288321 Alzheimer's disease ; 3-(2,3-dihydro-5,6-difluorobenzofur-7-yl)-4-[1-(piperidin-4-yl)-1H-indol-3-yl]pyrrole-2,5-dione; stimulating bone deposition
12/29/2005US20050288320 Induce biosymthesis of cytokines, interferons, tumor necrosis factor; antitumor agents; viricides; chemical intermediates
12/29/2005US20050288318 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics
12/29/2005US20050288317 Amido compounds and their use as pharmaceuticals
12/29/2005US20050288316 Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists
12/29/2005US20050288315 4-((7-chloroquinolin-4-yl)aminoalkyleneamino-)-spiro(cyclohexane-1.5'-1H-4,5,6-trioxaindene )dicitrate; malaria; paraciticides; antiprotozoa agents; Plasmodium; synergistic; chloroquine-resistant; cost efficiency; industrial scale; penetration and activity of artemisine
12/29/2005US20050288313 Synergistically combined with immunomodulators or antiinflammtory agents; treating rheumatoid arthritis; inhibiting organ transplant rejection; Janus Kinase 3 inhibitors such as CP 690550, 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile
12/29/2005US20050288312 Bicyclic pyridine and pyrimidine p38 kinase inhibitors
12/29/2005US20050288310 Methods of treating cellular proliferative disease using naphthalimide and PARP-1 inhibitors
12/29/2005US20050288308 11B-HSD1 inhibitors for the treatment of diabetes
12/29/2005US20050288307 Anti-viral compounds
12/29/2005US20050288306 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
12/29/2005US20050288305 N-biarylmethyl aminocycloalkanecarboxamide derivatives
12/29/2005US20050288304 Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists
12/29/2005US20050288303 Cyclic protein tyrosine kinase inhibitors
12/29/2005US20050288300 Modulating metabolism of maxillary sinus pathogenic bacteria by contacting maxillary sinus pathogenic bacteria with an antibacterially effective amount of a gemifloxacin compound; treating sinusitis
12/29/2005US20050288299 Preferably p38-alpha; azaindoles, azabenzofurans, or azabenzothiophenes are coupled through a piperidine or piperazine type linker to another cyclic moiety; antiarthritic, anticarcinogenic, antiinflammatory agents; analgesics
12/29/2005US20050288298 Methods for the treatment of synucleinopathies
12/29/2005US20050288297 {4-[6-methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl]piperazinyl}-N-[4-(methylethoxy)phenyl]carboxamide; inhibits phosphorylation of platelet-derived growth factor receptor to hinder abnormal cell growth/wandering; cancer; arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis
12/29/2005US20050288296 2,3-Dimethylindolo[2,3-b]quinoxaline-6-yl-acetamide; 9-Chloro-2,3-dimethyl-6-(aminoethylamino-2-oxoethyl)-6H-indolo[2,3-b]quinoxaline; autoimmune diseases
12/29/2005US20050288295 Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
12/29/2005US20050288294 N-ethyl-N'-{(3R)-1-[4-(3-phenylthieno[3,4-b]pyrazin-2-yl)benzyl]pyrrolidin-3-yl}urea; inhibit activity of a serine, threonine protein kinase; cancer
12/29/2005US20050288293 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors
12/29/2005US20050288292 Pharmaceutical formulation and its use in the treatment of inner ear diseases
12/29/2005US20050288291 Modulation of cell fates and activities by phthalazinediones
12/29/2005US20050288290 e.g. 1-(4-(6-Chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)-3-fluorophenyl)-3-(2-(4-fluorophenyl)acetyl)thiourea; mitogen-activated protein kinase inhibitor; anticarcinogenic agent, angiogenesis inhibitor; solid tumor, leukemia
12/29/2005US20050288289 Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
12/29/2005US20050288288 Methods for preparing P2X7 inhibitors
12/29/2005US20050288287 Chiral cis-imidazolines
12/29/2005US20050288286 Anti-inflammatory medicaments
12/29/2005US20050288285 Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
12/29/2005US20050288284 Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders
12/29/2005US20050288283 Topical formulations for treating allergic diseases
12/29/2005US20050288282 Anticancer agents; antiproliferative agents
12/29/2005US20050288281 Hetero isonipecotic modulators of vanilloid VR1 receptor
12/29/2005US20050288280 Meloxicam in veterinary medicine
12/29/2005US20050288279 Phenothiazine derivatives and their method of use
12/29/2005US20050288278 HIV replication inhibiting pyrimidines
12/29/2005US20050288277 Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S)-2,3-benzodiazepine
12/29/2005US20050288276 Pharmaceutical formulation of olanzapine
12/29/2005US20050288275 New compounds
12/29/2005US20050288274 Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane
12/29/2005US20050288273 Antibacterial agents
12/29/2005US20050288272 Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
12/29/2005US20050288271 Arylsulfonamides and uses related thereto
12/29/2005US20050288270 New aminopyridine derivatives and their use as pharmaceuticals
12/29/2005US20050288267 Estradiol prodrugs
12/29/2005US20050288266 Combinations comprising antimuscarinic agents and corticosteroids
12/29/2005US20050288265 Novel combination of glucocorticoids and pde-4 inhibitors for treating respiratory diseases, allegic diseases, asthma and copd
12/29/2005US20050288264 Dosage Regimen and Pharmaceutical Composition for Emergency Contraception
12/29/2005US20050288263 2-(&agr;-Hydroxypently) benzoate and its preparation and use
12/29/2005US20050288262 such as 3,10-Dibenzyloxyminocycline, used to treat bacterial infections and neoplasms, as well as blocking tetracycline efflux and modulation of gene expression
12/29/2005US20050288261 Compositions and method for treating infection in cattle and swine
12/29/2005US20050288260 Novel nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same
12/29/2005US20050288259 Composition
12/29/2005US20050288258 Compounds, compositions and methods for treating or preventing viral infections and associated diseases
12/29/2005US20050288257 Novel stable compositions of water and oxygen sensitive compounds and their method of preparation
12/29/2005US20050288256 Methods for preparing P2X7 inhibitors
12/29/2005US20050288255 Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
12/29/2005US20050288254 Treating sepsis or septic shock by administering 1-stearoyl, 1-palmitoyl-, 1-myristoyl- lysophosphatidylcholine, or 1-oleoyllysophosphatidylcholine or sphingosylphosphorylcholine.
12/29/2005US20050288253 Boronic acid salts
12/29/2005US20050288252 Composition for stimulating bone growth and differentiation and method for isolating same
12/29/2005US20050288251 O-acylated heparin; coating for stents; administered near or into a site of a tumor to decrease size or cease the growth of the malignancy
12/29/2005US20050288250 Novel use of carbohydrates and compositions
12/29/2005US20050288249 Testing a compound for the ability to inhibit PKG I alpha; testing the compound for the ability to inhibit PKG I beta; identifying the compound as a candidate drug useful in the treatment of pain ifit selectively inhibits PKG I alpha relative to PKG I beta .
12/29/2005US20050288248 Polypeptide; polyethylene glycolylated polypeptide; antidiabetic agents; side effect reduction
12/29/2005US20050288240 Conversion by human liver microsomes to MPO3H2; hepatitis, cancer, liver fibrosis, malaria, other viral and parasitic infections, and metabolic diseases where the liver is responsible for the overproduction of the biochemical end product, diabetes; enhanced oral drug delivery
12/29/2005US20050288239 Anticancer glycoside compounds
12/29/2005US20050288238 Benzocyclodecane derivatives with antitumor activity
12/29/2005US20050288237 Novel derivative of flavone c-glycoside and composition containing the same
12/29/2005US20050288236 Substituted fullerene formulations and their use in ameliorating oxidative stress diseases or inhibiting cell death
12/29/2005US20050288235 Sodium chloride; dextran, carboxymethyl starch, sodium alginate, pentahydroxyethyl starch, gelatin derivatives or pectin; NaHCO3, KCl, MgSO4, CaCl, calcium gluconate, calcium lactate, sodium lactate, and/or Tris buffer; total Na ion does not exceed equivalent concentration of 6.9% (w/v); traumatic shock
12/29/2005US20050288234 administering (R)-2-acetamido-N-benzyl-3-methoxypropionamide; tremor comprises rhythmic oscillatory movement
12/29/2005US20050288230 Non-steroidal anti-androgen therapy
12/29/2005US20050288225 Modulators of intracellular inflammation, cell death and cell survival pathways
12/29/2005US20050288222 Methods for enhancing the bioavailability of a drug
12/29/2005US20050288215 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure
12/29/2005US20050288213 Combination therapy for the treatment of obesity
12/29/2005US20050288187 Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
12/29/2005US20050287665 Using stem cell culture comprising dibutyryl cAMP and pituitary adenylate cyclase-activating polypeptide (PACAP) as therapeujtic treating spinal cord injuries
12/29/2005US20050287617 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
12/29/2005US20050287605 Caspase 3 inhibitors
12/29/2005US20050287603 Modulation of bone development
12/29/2005US20050287530 TCL-1b gene and protein and related methods and compositions
12/29/2005US20050287521 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof
12/29/2005US20050287494 Gingival retraction material
12/29/2005US20050287232 Skin immune function controlling agents
12/29/2005US20050287230 Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof
12/29/2005US20050287228 Method and composition for improving fertility health in female and male animals and humans
12/29/2005US20050287227 Supplement containing carotenoid, nicotinamide, zinc, water soluble extract of uncaria species and method of the same
12/29/2005US20050287226 High potency clinical anti-craving treatment and method of use
12/29/2005US20050287220 solvent selected from glycerol formal, ethyl lactate, and hydroxypropyl methylcellulose; antibacterial agent, antifungal agent, antiparasitic agent, antiyeast agent, antiviral agent, antiinflammatory agent; gel for controlled or sustained release; infection of the skin, ear, or eye; veterinary medicine
12/29/2005US20050287219 Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
12/29/2005US20050287217 Transdermal delivery system for water insoluble drugs
12/29/2005US20050287213 Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
1 ... 4417 4418 4419 4420 4421 4422 4423 4424 4425 4426 4427 4428 4429 4430 4431 4432 4433 4434 4435 4436 4437 ... 7860